Abstract:Expression profiling of microRNAs (miRNAs) in most diseases might be popular and provide the possibility for diagnostic implication, but few studies have accurately quantified the expression level of dysregulated miRNAs in acute myeloid leukemia (AML). In this study, we analyzed the peripheral blood mononuclear cells (PBMCs) from 10 AML patients (subtypes M1 to M5) and six normal controls by miRNA microarray and identified several differentially expressed miRNAs. Among them miR-29a and miR-142-3p were selectiv… Show more
“…This finding is universal among the five AML subtypes according to French-American-British classification, i.e. M1, M2, M3, M4 and M5, and may function jointly in granulopoiesis and monopoiesis 97 . Microarray platform used to perform genome wide miRNome analysis of AML samples and normal progenitor CD34 + cells identified molecular signatures associated with several cytogenetic groups.…”
mentioning
confidence: 63%
“…Follow-up study on the influence of miR-29 and miR-142-3p on hematopoiesis in AML demonstrated a positive effect of these miRNAs on the monocytic and granulocytic differentiation (myeloid differentiation) and validated three targets involved in AML development. They used leukemia cell lines NB4, HL60, and THP-1, in which up-regulation of miR-29a and miR-142-3p expression during all-trans-retinoic acid (ATRA)-induced granulocytic differentiation and phorbol 12-myristate 13-acetate (PMA)-induced monocytic differentiation was observed 97 . It is conceivable that miR-29a and miR-142-3p promote myeloid differentiation primarily by affecting CCNT2, CDK6 and TAB2.…”
Aims. MicroRNAs of the miR-29 family members were one of the first microRNAs identified as possible therapeutic agents in malignant hematopoiesis. The aim of our review is to summarize the current state of knowledge on miR-29 family members. Methods. We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML). We also searched for subgroups of hematological malignancies, e.g. multiple myeloma, that are regarded as members of the acute or chronic types of leukemias. Results. A number of genes appear to be regulated by miR-29 family members in various physiological and pathological situations. In our view regulation of Tcl-1, Mcl-1 and DNA methyltransferases is relevant in case of hematological malignancies, hence these are the focus of this review. miR-29 family members also function during normal T-cell and B-cell development. Conclusion. MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment.
“…This finding is universal among the five AML subtypes according to French-American-British classification, i.e. M1, M2, M3, M4 and M5, and may function jointly in granulopoiesis and monopoiesis 97 . Microarray platform used to perform genome wide miRNome analysis of AML samples and normal progenitor CD34 + cells identified molecular signatures associated with several cytogenetic groups.…”
mentioning
confidence: 63%
“…Follow-up study on the influence of miR-29 and miR-142-3p on hematopoiesis in AML demonstrated a positive effect of these miRNAs on the monocytic and granulocytic differentiation (myeloid differentiation) and validated three targets involved in AML development. They used leukemia cell lines NB4, HL60, and THP-1, in which up-regulation of miR-29a and miR-142-3p expression during all-trans-retinoic acid (ATRA)-induced granulocytic differentiation and phorbol 12-myristate 13-acetate (PMA)-induced monocytic differentiation was observed 97 . It is conceivable that miR-29a and miR-142-3p promote myeloid differentiation primarily by affecting CCNT2, CDK6 and TAB2.…”
Aims. MicroRNAs of the miR-29 family members were one of the first microRNAs identified as possible therapeutic agents in malignant hematopoiesis. The aim of our review is to summarize the current state of knowledge on miR-29 family members. Methods. We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML). We also searched for subgroups of hematological malignancies, e.g. multiple myeloma, that are regarded as members of the acute or chronic types of leukemias. Results. A number of genes appear to be regulated by miR-29 family members in various physiological and pathological situations. In our view regulation of Tcl-1, Mcl-1 and DNA methyltransferases is relevant in case of hematological malignancies, hence these are the focus of this review. miR-29 family members also function during normal T-cell and B-cell development. Conclusion. MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment.
“…Serum miR-142-3p was identified to be associated with a high recurrence risk in patients with early-stage lung adenocarcinoma, and was a putative serum marker for risk assessment (40). The expression levels of miR-142-3p and miR-29a in peripheral blood mononuclear cells may be used as novel diagnostic markers with ~90% sensitivity and ~100% specificity for the diagnosis of acute myeloid leukemia (41). During human bronchial squamous carcinogenesis, miR-142-3p, which is typically upregulated during lung development, was first downregulated at the earliest stages of carcinogenesis, and was also subsequently upregulated during later stages, suggesting that the expression of miR-142-3p may be monitored to assess cancer development (42).…”
Abstract. MicroRNAs (miRNAs/miRs) serve an important role in the regulation of carcinogenic pathways. RCC is the most prevalent kidney cancer that occurs in adults. miRNAs have gained increasing attention due to their association with RCC tumorigenesis, serving as biomarkers for early detection and progression monitoring, and as potential targets for molecular therapy. Upregulation of miRNA-142-3p has been previously identified in RCC tissues by microarray profile, however, its expression and function in RCC have not yet been validated. In the present study, quantitative polymerase chain reaction was performed to quantify the relative expression of miR-142-3p in 53 paired RCC and adjacent normal tissues. Furthermore, wound healing, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and flow cytometry assays were performed to analyze the impacts of miR-142-3p on cellular migration, proliferation and apoptosis. The results demonstrated that miR-142-3p was significantly upregulated in RCC tissues compared with adjacent normal tissues. Downregulation of miR-142-3p, induced by chemically synthesized miR-142-3p inhibitor, significantly suppressed cell migration and proliferation, and promoted cell apoptosis in 786-O and ACHN cells, supporting the theory that miR-142-3p may function as an oncogene in RCC. The potential clinical significance of miR-142-3p, as a biomarker and therapeutic target, provides rationale for further investigation into the miR-142-3p-mediated molecular pathway and how it is associated with RCC development.
“…These data suggest that loss of target control by miR-142 may be a novel mechanism in the pathogenesis of leukemia. Guido Kobbe, 3 Gesine Bug, 4 Oliver Ottmann, 4 Wolf-Karsten Hofmann, 5 Nicolaus Kröger, 6 Walter Fiedler, 7 Richard Schlenk, 8 Konstanze Döhner, 8 Hartmut Döhner, 8 Jürgen Krauter, 1,9 …”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.